Insiders · CPRX

Daniel J. Curran

Director at Catalyst Pharmaceuticals, Inc. (CPRX) since August 2025

Daniel J. Curran has filed 9 insider reports with the SEC since June 2024, as director at Catalyst Pharmaceuticals, Inc. (CPRX), director at Xilio Therapeutics, Inc. (XLO) and director at Alx Oncology Holdings Inc (ALXO). The latest filing, on July 17, 2026, reports sale back to the company at Catalyst Pharmaceuticals, Inc. (CPRX).

Filings
9
Companies
3
Bought on market
None
Sold on market
None

Companies where Daniel J. Curran is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Catalyst Pharmaceuticals, Inc. logo
CPRX
Catalyst Pharmaceuticals, Inc.
Directorsince August 20250Jul 17, 2026
Xilio Therapeutics, Inc. logo
XLO
Xilio Therapeutics, Inc.
Director$7.63Jun 12, 2026
Alx Oncology Holdings Inc logo
ALXO
Alx Oncology Holdings Inc
Directorsince August 2025$0.9701Jan 21, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Daniel J. Curran with

Other insiders at the same companies

Questions about Daniel J. Curran

What is Daniel J. Curran's role at Catalyst Pharmaceuticals, Inc.?
Daniel J. Curran reports to the SEC as director at Catalyst Pharmaceuticals, Inc. (CPRX), according to the latest filing on July 17, 2026. Daniel J. Curran has also filed as director at Xilio Therapeutics, Inc. (XLO) and director at Alx Oncology Holdings Inc (ALXO).
Has Daniel J. Curran bought or sold stock recently?
No open-market purchases or sales by Daniel J. Curran are on file. The filings report sale back to the company and grant or award.
How do I get alerts when Daniel J. Curran files?
Follow Daniel J. Curran on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Daniel J. Curran (SEC CIK 0001887599). Totals count each trade once, skipping amendments whose original is on file, from Jun 17, 2024 on. View on SEC EDGAR